// App-Quantinova.ai

163 : Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.

Researchers

Presenter

  • Howard I. Scher

Principal Investigators

  • Ryon Graf

  • Jessica Louw

  • Adam Jendrisak

  • Ann Johnson

  • Stephanie Greene

  • Angel Rodriguez

  • Nicole A. Schreiber

  • Brigit McLaughlin

  • Lyndsey Dugan

  • Martin Fleisher

  • Jerry Lee

  • Yipeng Wang

  • Dena C. Marrinucci

  • Mark Landers

  • Ryan Vance Dittamore

Medical Centers

  • Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Epic Sciences, Inc., San Diego, CA

  • Epic Sciences, Inc., San Diego, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved